Open AccessComparative onset of immunity of oral and intranasal vaccines against challenge with Bordetella bronchiseptica
Author(s) -
ScottGarrard Maya M,
Chiang YuWei,
David Frederic
Publication year - 2018
Publication title -
veterinary record open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.504
H-Index - 12
ISSN - 2052-6113
DOI - 10.1136/vetreco-2018-000285
Subject(s) - bordetella bronchiseptica , nasal administration , medicine , bordetella , immunity , immunology , virology , immune system , biology , bordetella pertussis , bacteria , genetics
Three groups of approximately eight‐week‐old beagles were vaccinated once with 1 ml of placebo vaccine (oral, n=9), 1 ml of Recombitek® Oral Bordetella (oral, n=10) or 1 ml Nobivac® Intra‐Trac 3 (intranasal, 0.5 ml/nostril, n=10). Seven days after vaccination, the three groups were challenged with virulent Bordetella bronchiseptica via aerosolisation. Eight of nine dogs in the placebo group and no dogs in the Recombitek® Oral Bordetella or Nobivac® Intra‐Trac 3 vaccine groups developed spontaneous cough of two or more consecutive days (disease case definition). Dogs in the Recombitek® Oral Bordetella and Nobivac® Intra‐Trac 3 groups had a significantly lower incidence of disease (P<0.0001) with a 100 per cent preventable fraction. The study demonstrated that vaccination with either Recombitek® Oral Bordetella or Nobivac® Intra‐Trac 3 is effective in preventing disease seven days after vaccination when compared with dogs vaccinated with a placebo.